![Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges - ScienceDirect Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0304394019303842-gr2.jpg)
Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges - ScienceDirect
![A guide in lentiviral vector production for hard-to-transfect cells, using cardiac-derived c-kit expressing cells as a model system | Scientific Reports A guide in lentiviral vector production for hard-to-transfect cells, using cardiac-derived c-kit expressing cells as a model system | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-98657-7/MediaObjects/41598_2021_98657_Fig7_HTML.png)
A guide in lentiviral vector production for hard-to-transfect cells, using cardiac-derived c-kit expressing cells as a model system | Scientific Reports
![Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors: Molecular Therapy - Methods & Clinical Development Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors: Molecular Therapy - Methods & Clinical Development](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ba083c2b-fc39-489c-9158-ab774335d923/gr1_lrg.jpg)
Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors: Molecular Therapy - Methods & Clinical Development
![The TOP vector: a new high-titer lentiviral construct for delivery of sgRNAs and transgenes to primary T cells: Molecular Therapy - Methods & Clinical Development The TOP vector: a new high-titer lentiviral construct for delivery of sgRNAs and transgenes to primary T cells: Molecular Therapy - Methods & Clinical Development](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/766ca309-467d-4cb4-a1ce-c502735cc18f/fx1_lrg.jpg)
The TOP vector: a new high-titer lentiviral construct for delivery of sgRNAs and transgenes to primary T cells: Molecular Therapy - Methods & Clinical Development
![Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice | Human Gene Therapy Methods Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice | Human Gene Therapy Methods](https://www.liebertpub.com/cms/10.1089/hgtb.2017.098/asset/images/medium/figure1.gif)
Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice | Human Gene Therapy Methods
![Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases - ScienceDirect Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2329050121001790-fx1.jpg)
Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases - ScienceDirect
![Experimental design for stable genetic manipulation in mammalian cell lines: lentivirus and alternatives - Shearer - 2015 - Genes to Cells - Wiley Online Library Experimental design for stable genetic manipulation in mammalian cell lines: lentivirus and alternatives - Shearer - 2015 - Genes to Cells - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d8bbca5a-86fe-474a-a03b-2f97fa19658c/gtc12183-fig-0001-m.jpg)